Nisotirostide  (Synonyms: LY-3457263)

Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity^[1].

4974.53

C₂₃₀H₃₄₃N₅₉O₆₅

2663844-45-7

Chain1:Pro-Lys-Pro-Glu-Lys-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Trp-Gln-Arg-Tyr-Tyr-Ala-Glu-Leu-Arg-His-Tyr-Leu-Asn-Trp-Leu-Thr-Arg-Gln-Arg-Tyr-NH2; Chain2:Ggu-Ggu-Oaa (Amide bridge:Chain1 Lys5-Chain2 Oaa3)

Chain1:PKPEKPGEDASPEEWQRYYAELRHYLNWLTRQRY-NH2; Chain2:Ggu-Ggu-Oaa (Amide bridge:Chain1 Lys5-Chain2 Oaa3)

OC1=CC=C(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]2N(CCC2)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@H]3N(CCC3)C([C@@H](NC([C@@H](NC([C@H]4N(CCC4)C([C@@H](NC([C@H]5NCCC5)=O)CCCCN)=O)=O)CCC(O)=O)=O)CCCCNC(CCCCCNC([C@@H](NC(CC[C@H](NC(CCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)CCC(O)=O)=O)=O)=O)=O)=O)CCC(O)=O)=O)CC(O)=O)=O)C)=O)CO)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CC6=CNC7=C6C=CC=C7)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)CC8=CC=C(C=C8)O)=O)CC9=CC=C(C=C9)O)=O)C)=O)CCC(O)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)CC%10=CNC=N%10)=O)CC%11=CC=C(C=C%11)O)=O)CC(C)C)=O)CC(N)=O)=O)CC%12=CNC%13=C%12C=CC=C%13)=O)CC(C)C)=O)[C@@H](C)O)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)C(N)=O)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kloock S, et al. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? Pharmacol Ther. 2023 Nov;251:108549.  [Content Brief]